Biotech’s 2019 “Plot Twist”
After a rough end to 2018, with massive fund outflows in the fourth quarter, biotech’s condition has been improving in 2019 – and these two… Read More »Biotech’s 2019 “Plot Twist”
After a rough end to 2018, with massive fund outflows in the fourth quarter, biotech’s condition has been improving in 2019 – and these two… Read More »Biotech’s 2019 “Plot Twist”
Small caps have started 2019 off strong, and they may be impossible for investors to ignore going forward. European small caps, that is. CLICK HERE.
Fintech is one of the big buzzwords these days, referring to innovative technologies that seek to improve and automate the delivery of financial services. And… Read More »This New ETF Is All About Disruption
Palladium has been the best-performing commodity for two years straight, with the price of the precious metal even recently surpassing that of gold for the… Read More »Mining Opportunity In Palladium’s Surge
As the next step in the driverless car revolution nears, many automakers are backing away from it. Here’s why – and which automaker stocks may… Read More »The Driverless Car Detour
She is one of the most influential women on Wall Street and the visionary behind Ellevest, the first ever digital investment platform for women. Here’s… Read More »Investing With One Of The Street’s Most Influential Women
With a promising cannabinoid pipeline, an alternative to the EpiPen, and a superior solution for opioid overdoses, this firm has moved in on not one… Read More »Therapeutic Trifecta
Energy demand is expected to increase by 25% by 2040, as an additional 1.7 billion new people are added to the global population. This creates… Read More »How To Clean Up In Clean Energy
If 2018 was the “Year of Hope” for pot stocks, 2019 may be best viewed as the “Year of Reality” – with plenty of opportunities… Read More »From Hope To Reality: The Pot Trade In 2019
After finding itself among the most oversold sectors last year, biotech is having its best start to a year since 2012 – a rally fueled… Read More »Biotech Is On The Mend